406 - Effectiveness of the JN.1-adapted BNT162b2 COVID-19 Vaccine in High-Risk Groups against Hospitalization in Europe: A Test-Negative Case-Control using the id.DRIVE Platform

Presenting Author(s)

• HV

  Hannah R. Volkman, PhD, MPH

  Director, Global Scientific Affairs - Covid & Flu
  Pfizer
  New York, New York, United States

  Slides

Co-Author(s)

• Ld

  Leonie de Munter, PhD

  P95 Epidemiology and Pharmacovigilance
  Leuven, Brabant Wallon, Belgium
• TT

  Thao M.P. Tran, PhD

  P95 Clinical and Epidemiology Services
  Leuven, Vlaams-Brabant, Belgium
• CM

  Cátia Marques, MSc

  Pfizer Inc.
  Lisbon, Lisboa, Portugal
• EM

  Elisabeth J. Mesfun-Kap, PhD

  P95 Clinical and Epidemiology Services
  Rotterdam, Zuid-Holland, Netherlands
• LC

  Laura Choi, MPH

  Pfizer Inc.
  New York, New York, United States
• HD

  Hollie Dunford, BSc

  P95 Clinical and Epidemiology Services
  Durham, North Carolina, United States
• SV

  Srinivas Valluri, PhD

  Pfizer Inc
  New York, New York, United States
• JH

  Juan V. Hernandez-Villena, MSc

  P95 Clinical and Epidemiology Services
  Leuven, Vlaams-Brabant, Belgium
• JY

  Jingyan Yang, MHS, DrPH

  Pfizer and Columbia University Institute for Social and Economic Research and Policy
  New York, New York, United States
• SA

  Sultan Abduljawad, PhD

  BioNTech UK Ltd.
  London, England, United Kingdom
• IC

  Irma Casas, PhD

  Hospital Universitari Germans Trias i Pujol
  Badalona, Catalonia, Spain
• EM

  Elisa Martró, PhD

  Hospital Universitari Germans Trias I Pujol
  Badalona, Catalonia, Spain
• BG

  Beate Grüner, MD

  University Hospital Ulm
  Ulm, Baden-Wurttemberg, Germany
• AM

  Ainara Mira-Iglesias, PhD

  Fisabio Public-Health
  Valencia, Comunidad Valenciana, Spain
• CO

  Carlos M. Oñoro-López, MD

  Hospital Universitario La Paz
  Madrid, Madrid, Spain
• OP

  Oleguer Parés-Badell, MD

  Hospital Universitari Vall d'Hebron
  Barcelona, Catalonia, Spain
• 

  Alejandro Orrico-Sánchez

  Senior Manager
  FISABIO-Public Health
  Valencia, Comunidad Valenciana, Spain
• SO

  Susana Otero-Romero, PhD

  Hospital Universitario Vall d’Hebrón
  Barcelona, Catalonia, Spain
• AT

  Antoni Torres, MD, PhD

  Professor of Medicine
  Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES
  Barcelona, Catalonia, Spain
• FM

  Federico Martinon-Torres, MD, PhD, Assoc. Prof

  Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
  Santiago de Compostela, Galicia, Spain
• JN

  Jennifer L Nguyen, ScD, MPH

  Pfizer Inc.
  New York, New York, United States
• KB

  Kaatje Bollaerts, PhD

  P95 Epidemiology and Pharmacovigilance
  Leuven, Brabant Wallon, Belgium